Pro Share Advisors LLC Provention Bio, Inc. Transaction History

Pro Share Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$6.7 - $24.21 $82,825 - $299,284	12,362 Added 80.65%	27,690 $667,000
Q4 2022 Feb 02, 2023	BUY	$4.52 - $10.57 $8,908 - $20,833	1,971 Added 14.76%	15,328 $162,000
Q3 2022 Nov 04, 2022	BUY	$3.43 - $5.62 $7,141 - $11,700	2,082 Added 18.47%	13,357 $61,000
Q2 2022 Aug 01, 2022	SELL	$3.65 - $7.3 $20,739 - $41,478	-5,682 Reduced 33.51%	11,275 $45,000
Q1 2022 May 10, 2022	SELL	$3.4 - $7.88 $13,872 - $32,150	-4,080 Reduced 19.39%	16,957 $125,000
Q4 2021 Feb 08, 2022	BUY	$5.59 - $7.39 $2,185 - $2,889	391 Added 1.89%	21,037 $118,000
Q3 2021 Nov 12, 2021	SELL	$5.66 - $8.33 $29,030 - $42,724	-5,129 Reduced 19.9%	20,646 $132,000
Q2 2021 Aug 13, 2021	BUY	$6.71 - $11.04 $19,009 - $31,276	2,833 Added 12.35%	25,775 $217,000
Q1 2021 May 14, 2021	BUY	$10.12 - $19.45 $37,221 - $71,537	3,678 Added 19.09%	22,942 $241,000
Q4 2020 Feb 09, 2021	BUY	$11.79 - $18.94 $227,122 - $364,860	19,264 New	19,264 $326,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.